noth come noth pipelin concern
initi coverag under-perform rate
tp life beyond aducanumab like remain challeng
core base busi ms spinraza like declin near term
weak pipelin like abl yield revenu earn growth
struggl recov late-stag discontinu
alzheim program ytd vs ibb expect
see downsid catalyst vs upsid opportun next year
risk sma busi competit entri spinraza
unlik product treat sma upcom approv gene
therapi given increas newborn screen sma could see share
lost incid market beyond gene therapi also concern
roch oral splice modul could take share preval market
priorit share repurchas transform like accret
near-term ep expens long-term growth
concern manag focu share repurchas return capit
sharehold think absent clear growth strategi includ
accret price-to-earnings multipl could compress long run
analysi suggest growth-focus could yield better return
ms busi stabl near term yet headwind mount
proprietari ms physician survey indic increas tysabri eros due
ocrevu tecfidera use remain stabl crowd new
oral could hamper long-term sale also see increas risk
recent ipr file dose patent earli rule expect
valuat risk valu share use dcf analysi result
busi develop
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater-than-expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater-than-expect rate new therapi take greater
expect share near term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
tabl content
guidanc consensu expect
unlik remain leader sma increas competit
 may increasingli import examin potenti scenario
tepid sentiment around pipelin recent acquisit nightstar
proprietari survey suggest ms franchis could face challeng ocrevu
crowd oral segment
biosimilar busi gener end-us sale still
enough differenti growth
holt view
cs peer relationship biogen
alzheim aducanumab
franchis becom appar
viewlif beyond aducanumab put renew focu base busi
pipelin clear need share repo commercial-
focus market develop
therapeut treat neurolog condit much histor top-lin growth
tie compani multipl sclerosi ms franchis recent sma
spinal muscular atrophi rare neuromuscular diseas franchis pipelin failur
caus us question sourc long-term growth current price-to-earnings multipl
decreas recent prior aducanumab failur
discount peer concern could compress challeng
futur growth prospect diminish
manag focus share repurchas primari capit alloc strategi
pleas see industri report detail larg cap biotech sector
furthermor look share basi much higher
peer ratio vs large-cap peer includ high-growth
vertex cost rel earn growth much higher far less certain vs peer
neg thesi base follow main concern current pipelin
like support futur earn revenu growth near-term sma challeng
like fulli reflect consensu forecast could compress multipl
posit buyer posit weak believ
way compani address long-term growth buy revenu view
next month downsid risk remain higher believ neg updat
either intern competit could drive stori given reason
initi coverag under-perform tp
valuat dcf base case model share use discount
cash flow dcf analysi assum wacc weight averag cost capit
termin growth rate project cash flow year assum
risk commerci risk commerci busi perform better
anticip could see share appreci clinic development risk
unexpect pipelin success posit updat across earli mid-stag pipelin
could posit impact share intellectu properti ip risk abl
success defend extend ip key product busi develop risk
current assum low level busi develop deviat strategi
unclear path forward aducanumab failur follow decis discontinu
phase develop aducanumab face believ clear
challeng establish execut strateg path forward past
year share price close tie increment updat aducanumab
program highlight investor focu alzheim diseas ad
think without ad program believ unlik work
well growth stori remain murki meaning de-risk pipelin
proprietari physician survey suggest ms busi could face headwind
ocrevu challeng tysabri tecfidera oral market continu
crowd key take-away survey physician satisfact ocrevu
high increasingli attract option like expens tysabri
despit gener satisfact histor ocrevu usag treatment-nav set
remain low larger increas expect treatment-experienc set
oral therapi unlik see signific eros ocrevu note
crowd could affect tecfidera survey low prescrib awar
vumer novel ms oral therapi lower gastrointestin side effect vs
tecfidera could indic lacklust launch pdufa octob
furthermor prescrib indic excit next-gener oral
declin ms remain core compon revenu base absent
signific pipelin acquisit ms remain core compon base
busi believ contract credit suiss five-year compound-annual-growth-rate
consensu tecfidera screen well survey crowd oral space
like problem ocrevu like take share tysabri
econom asset revenu lost tysabri like made
ocrevu royalti long term project declin growth product sale
competit next-gener oral therapi affect vumer commerci
mount issu biogen sma franchis increas impact gene
therapi novel oral see direct competit novartiss gene
therapi product zolgensma pdufa expect may could use
primari treatment newli diagnos patient replac ahead biogen spinraza
gene therapi could differenti single-tim dose compar chronic
administr spinraza roche/ptc risdiplam could direct competitor
also target protein oral avail data present world muscl
societi meet updat american academi neurolog meet earlier
may meet data posit
think spinraza incid market newli diagnos patient type sma
like shift zolgensma especi rise newborn screen preval
market could also threaten roche/ptc risdiplam continu show efficaci
believ oral option could prefer intrathec inject view
revenu risk risdiplam appreci
pipelin asset al stroke pain ad less meaning us
biogen earlier pipelin vari gener less excit
program program think stroke treatment program cirara
rel best posit phase success note mix phase data give us
reason cautiou also cautiou pain program vixotrigine/
given phase data trigemin neuralgia fail meet primari endpoint
link manuscript recent present earli phase data
interest howev note trial patient genet
variant amyotroph later sclerosi al impact estim
continu invest poor use despit failur
aducanumab partner eisai continu develop
howev limit confid asset believ target beta
amyloid ad patient right way treat diseas base everi late-stag
failur seen date class includ aducanumab crenezumab
solanezumab bapineuzumab also littl confid elenbecestat
bace inhibitor yet see meaning efficaci drug class
failur aducanumab support amyloid-beta hypothesi
view invest anti-beta amyloid drug either via antibodi enzym inhibitor
miss opportun invest elsewher believ chanc
success anyth think target tau could better ad howev
limit data think prematur make clear call approach
focus share repurchas vs growth-focus flaw strategi
despit hole late-stag pipelin manag remain steadfast
use share repurchas principl strategi capit alloc might
prop share price balanc believ noth
address long-term need revenu earn growth think strategi
could warrant multipl contract growth prospect diminish
would rather see help rebuild pipelin beyond hard treat central
nervou system indic nightstar okay start note
opportun choroideremia x-link retin pigmentosa small reflect
rel low price paid compani
increas need undertak large-scal believ might need
undertak larger transact could includ compani
neurocrin sarepta market cap commercial-stag asset
transact contrari recent commentari compani indic sweet
spot transact earli stage think narr need chang
follow failur aducanumab assum premium compani
believ capac transact updat metric
provid cfo begin believ
capac assum current cash debt capac ebitda less
current total debt cash flow less announc share buyback
use methodolog see capac
howev believ order revers current
cours purchas remain optim solut think suffici capac
deal achiev someth meaning balanc like requir
strateg shift manag
larger transform deal like difficult possibl stock
debt issu challeng much transform would merger
compani alexion biomarin think merger alexion could
like given compani cash flow gener focu neurolog soliri gmg
gener myasthenia gravi nmosd neuromyel optica spectrum disord
headquart locat addit current cfo alexion use
make potenti integr smoother deal size would transform
compani potenti realiz signific effici potenti accret
ep five year believ larger pharma biotech lilli
would consid acquisit enough
meaning pipelin coupl matur base busi would make compani
poor strateg fit larger cap compani
manag focus share repurchas despit view need
engag larger-scal current board manag tradit taken
conserv approach avoid bigger later-stag deal
earn call manag reiter posit share repurchas current
best way use capit essenti compani laser-focus develop
aducanumab know drug work believ time
manag board re-think approach
view financi perspect biogen result fine non-gaap
ep line consensu expect revenu slightli ahead consensu
concern tone call manag focus
share repurchas primari avenu capit alloc compani
unabl comment futur partnership eisai develop
get signific strateg updat path forward biogen
near-term outlook believ share under-perform rel peer
broader market failur aducanumab phase trial caus
signific sell-off march littl point caus us
construct stock think base busi overst even
expect stabil ms franchis previous said capit alloc
focus share repurchas could warrant multipl contract dri
powder could spent growth use prop stock price
catalyst next month expect high-impact event
could support stock out-performance approv vumer phase data
opicinumab ms think low probabl success po given difficulti
anti-lingo program unlik enough significantli alter trajectori
franchis also see risk current ipr patent tecfidera
main revenu sourc rule expect earli readout earli
signific impact view lack meaning catalyst point
increasingli urgent realiti engag larger concern
competit sma fulli appreci competit updat drive downsid risk
share next month could see multipl compress
especi basi earn growth expens unlik
long-term outlook longer term without signific transact remain
neg share think continu invest anti-amyloid beta
treatment elenbecestat poor use resourc eisai
still engag collabor develop alzheim drug biosimilar busi
unlik replac revenu eros project base busi portfolio
limit must share econom samsung biolog furthermor
project lower estim biogen sma franchis take account loom
competit outsid signific invest acquisit restructur see
littl long-term upsid potenti rel peer
credit suiss view rel peer look profil vs large-cap
peer note follow key area concern base busi project
declin five-year compound-annual-growth-rate like limit pipelin upsid opportun
remain buyer posit weak think
immedi need transform yet manag focus share
guidanc consensu expect
top-lin estim within current revenu guidanc think beat
consensu forecast challeng even account
lower tax rate save discontinu aducanumab program
balanc think consensu revenu forecast across
commerci busi especi ms busi high below-consensu
revenu estim key driver below-consensu slightli below-guid
estim
follow failur aducanumab share recov
upsid spin raza continu strength despit gene therapi
launch success pipelin also see continu
durabl ms franchis despit increasingli competit
environ gener cash flow enabl continu
build late-stag pipelin use learn
aducanumab trial optim develop
anti-tau antibodi spinraza remain growth driver
uptak zolgensma slow risdiplam fail later-stag clinic
failur
share
aducanumab headwind across commerci busi
sma ms biosimilar biogen later-stag pipelin fail
yield success compani success acquir asset
compani fill late-stag pipelin continu
use resourc develop optim
earlier work key learn fail engag
emerg trial outlook remain challeng
like continu multipl compress growth struggl
becom appar
life beyond aducanumab remain challeng lost momentum across organ impact anticip
headwind across base ms sma busi magnifi investor littl els focu near term
unlik work highlight fail invest anti-beta amyloid drug becom reliant forc pay
premium acquir late-stag assert help replenish pipelin drive revenu growth next year despit
view increasingli urgent need acquir manag recent emphas believ best use capit
ii competit sma
biogen spinraza franchis remain growth driver revenu
earn competit novartiss zolgensma less
anticip roche/ptc risdiplam also competit threat
asset either fail late-stag trial show
significantli less efficaci spinraza spinraza sale peak
remain durabl long term
biogen spinraza franchis face headwind zolgensma
incid market risdiplam preval market zolgensma
abl take nearli entir share newli diagnos infant
newborn screen sma becom standard care risdiplam
demonstr impress efficaci late-stag trial becom
standard care replac spinraza
competit threat gene therapi like investor radar believ full impact lose incid
market bake number risdiplam shown good efficaci mid-stag trial like continu show efficaci
potenti replac spinraza incid market especi type patient see downsid risk stock
roche/ptc like provid increment data updat risdiplam next month
pipelin produc near-term upsid support stock
success across near-term pipelin includ
stroke cirara pain vixotrigin late-stag asset
nightstar acquisit notabl abl initi phase
trigemin neuralgia fda buy-in trial design
success complet phase cirara ischem stroke
launch gene-therapi product nightstar acquisit
earli posit pipelin updat continu support
share regardless alzheim program
biogen near-term pipelin fail deliv late-stag failur
across asset even asset success phase
fail gener signific cash flow justifi invest
replac lost revenu declin ms franchis product
acquir nightstar transact also unsuccess
late-stag clinic trial requir write-down
broad concern regard strength current franchis note mani asset highlight
compani either littl data unsuccess trial give us confid asset acquir nightstar shown
interest efficaci like small market meaning affect must acquir refil pipelin
aducanumab fail pay believ current pipelin support share upsid
charl martineau univers toronto figur credit suiss review biogen pipelin asset
associ schizophrenia
red indic area focu us
clinic trial
lupu cle sle
phase trial begin
phase trial begin
mylan ipr decis patent
phase rainbowfish trial start
reach trial start comer
one-year price target deriv base-cas dcf analysi
assum wacc wacc weight averag cost capit termin
growth rate project cash flow year assum fulli
dilut share outstand wacc line bloomberg wacc
rel gilead wacc higher believ futur
cash flow higher risk spinraza discuss throughout piec
ms franchis beyond key driver cash flow depend abil
develop commerci pipelin asset ophthalmolog neurolog longer-
term see risk current capit alloc strategi share repurchas
larger-scal help grow futur earn revenu assum neg
termin growth rate low confid abil develop
pipelin asset use base-cas dcf calcul target price
repres approxim downsid recent close price see
figur biogen dcf analysisbas
increas /decreas wc
dilut share current price
premium/ discount current
probabl success po estim across coverag univers gener
appli follow po estim asset variou stage develop enter
phase enter phase enter phase asset
nda/bla stage rare diseas patient assign standard
probabl phase phase phase bla/nda
assumpt fda work close manufactur design
implement clinic program also adjust po estim base clinic data
phase compel phase neg yet compani move
pivot trial assum pipelin rel lower probabl
success given limit clinic data previou neg trial see figur
sotp analysi major valuat base current ms franchis
valu share valu royalti ocrevu separ
market product vumer also separ yet approv
valu spinraza franchis valu biosimilar
collabor samsung valu royalti roch rituxan/
gazyva valu select pipelin asset valu
revenu valu share net unallocated/ corpor expens
cash equival debt result price target
dcf sensit analys includ two differ sensit analys help
support valuat look differ wacc tvgr termin valu growth
rate figur assum vari perform spinraza base potenti
competit use differ tvgr see figur first situat assum
neg growth tv still see dcf valuat lower
charl martineau univers toronto figur dcf sensit tvgr
scenario assum current
market ms franchis experi greater-than-expect degre eros
competit eros occur partial off-set sale vumer
spinraza remain standard care sma risdiplam zolgensma either fail
clinic/do take meaning share share repurchas lead
meaning accret constant improv multipl
grey grey scenario assum ms franchis
declin greater-than-expect rate new therapi take greater-than-expect
share near term zolgensma captur major new incid sma market
longer term spinraza lose share risdiplam preval sma market
capit deploy strategi fail gener meaning earn growth
share experi even greater degre multipl compress
commerci risk under-perform rate overal invest thesi
base assumpt ms busi face headwind
competit contract next year competitor fail
success develop commerci asset ms franchis
could better forecast also core thesi competit
sma market either competitor discuss zolgensma risdiplam fail take
share biogen spinraza actual result could higher estim
out-performance base busi versu estim could drive
clinic develop risk unexpect pipelin success posit
updat across earli mid-stag pipelin could posit impact
share current assign little-to-no valu mani pipelin asset howev
show promis result clinic trial could see posit re-
rate share
intellectu properti ip risk core thesi abl
success defend ip key product name tecfidera could see
share upsid investor becom comfort long-term
trajectori busi
busi develop risk current assum compani maintain
current level busi develop remain independ compani
focus capit deploy share repurchas versu large-scal
sort transform could posit affect share
unlik remain leader sma
near term expect like fda approv launch novartiss gene therapi
zolgensma sma neg affect share think spinraza could
soon lose share new incid market thesi believ biogen
unlik remain leader sma emerg competit gene therapi
zolgensma roche/ptc oral splice modul risdiplam view zolgensma
could captur signific share new patient incid popul particularli
type patient project overal increas new start zolgensma take market
share spinraza owe earlier newborn screen becom standard
care newborn babi highlight hh depart
servic ad sma recommend uniform screen panel rusp
newborn state level follow rusp guidelin option state
begun follow guidelin given trend increas newborn screen
think pre-symptomat patient diagnos treat right away
gene therapi time like erod incid market spinraza
think parent provid would opt initi treat seen durabl
treatment want use word cure long-term data
zolgensma also note declin actual new patient start
spinraza patient vs compani
attribut factor vs wareh potenti approv zolgensma
think potenti gene therapi like affect decis make
physician parent
beyond type newli diagnos patient think eventu potenti approv
risdiplam could take signific share preval market estim
larger see updat risdiplam program greater risk sentiment
around biogen sma franchis detail assess zolgensma
risdiplam provid sensit analysi around biogen sma franchis could
overal forecast significantli increas market eros competitor entri
peak spinraza sale approxim ww figur view
spinraza market vs consensu see five-year sale compound-annual-growth-rate vs
recent consensu expect see patient therapi end
ou total patient across geographi model
patient spinraza declin five-year compound-annual-growth-rate project
spinraza patient geographi type see figur see
signific eros start risdiplam zolgensma view spinraza
like under-perform consensu expect due competit
zolgensma newli diagnos patient popul risdiplam exist
risdiplam could impact long-term preval newli diagnos patient
market spinraza signific driver market eros pivot trial
roche/ptc risdiplam success could see headwind spinraza potenti
greater forecast risdiplam spinraza would provid addit effect
either/or situat could also see scenario patient opt
oral therapi vs intrathec inject spinraza patient develop scoliosi
sma could also good candid oral therapi given addit challeng
intrathec inject patient
figur credit suiss spinraza patient number geographi
base sma model spinraza account signific competit
risdiplam zolgensma across geographi assess biogen sma
busi discount spinraza benefit first-mov advantag
compel clinic trial real-world evid also realiz competit
product near-term horizon view zolgensma could provid
compel altern newli diagnos patient assum increas newborn
screen non-inferior efficacy/safeti furthermor zolgensma could provid better
long-term valu vs spinraza depend potenti list price durabl singl
treatment vs chronic see competit risdiplam conveni oral
dose potenti competit price note risdiplam small-
molecul oral administ splice modul could easier administ
need intrathec inject also like less costli manufactur orphan
drug price function address patient valu society/th health care
system cost manufactur sometim factor could see risdiplam undercut
price spinraza help drive usag
base case base current assumpt lose major
share newli diagnos market zolgensma model
assum patient diagnos newborn screen type
time diagnosi month therefor time proport type
patient would increas assum patient better candid
gene therapi model zolgensma captur exist
preval patient market also assum competit risdiplam begin
 gain preval market share follow
charl martineau univers toronto launch sma classif scenario see peak
ww sale declin figur detail
bear case assum zolgensma captur signific share
sma new incid popul preval opportun
base case model zolgensma launch year
europ japan come on-lin significantli reduc incid
popul treat spinraza key differ base
bear scenario assum risdiplam take major share
remain preval opportun view oral therapi differenti
better altern chronic intrathec inject assum efficacy/safeti
non-inferior result peak sale similar
base case see sale less base case see
figur detail
figur bear case risdiplam take major share preval opportun
bull case assum zolgensma captur signific share
sma new incid popul preval opportun
base case key differ base bull case
assum risdiplam approv spinraza abl maintain share
preval market key market result peak sale
higher peak sale base case see figur
figur bull case spinraza viabl option
clinic data point view think zolgensma could signific
threat spinraza posit phase interim phase data phase
start trial zolgensma compel nejm paper found
sever patient month event-fre surviv see figur note
spinraza use mani patient trial real world
pars nuanc zolgensma data start phase
phase trial note small number patient treat
saw impress rate event-fre surviv improv chop-intend
score see figur highlight novarti also pursu trial sma
type less sever form diseas could expand market zolgensma
think current data support base-cas scenario assum
signific competit novarti follow launch newli diagnos patient
new death report zolgensma phase add risk program
thesi chang highlight muscular dystrophi associ meet
one report patient die follow treatment zolgensma death
occur symptomat sma type patient six month old part
phase trial patient die follow sever respiratori infect
neurolog complic investig deem death potenti relat
treatment think enough warrant thesi chang regard
view type incid market highlight potenti risk zolgensma
program believ impact approv usag type infant
patient sever diseas death addit prior death deem
unrel therapi
event-fre surviv zolgensma
date interim data cut
mean chang averag chop-
intend score month
mean chang averag chop-
intend score month
turn back right left
sit without support second
stand assist
median durat follow-up data cut
median age data cut
patient older month
data pivot trial spinraza type sma patient endear link suggest
improv chop-intend rate scale neuromuscular disord
sever event-fre surviv overal surviv favor spinraza-tr patient vs
sham-control patient asid endear trial also provid data
nurtur trial link examin drug presymptomat infant later-onset
patient cherish nejm paper link think data spinraza
compel howev still believ data zolgensma point efficaci type
earli diagnos patient potenti better long-term durabl zolgensma could
differenti single-tim infus compar chronic intrathec inject
without head-to-head trial challeng make direct comparison
drug
pivot trial data support spinraza use type patient
symptomat presymptomat spinraza use exist patient
type highlight type patient pivot trial patient
treat spinraza aliv interim analysi hr favor
spinraza improv chop-intend score also highli signific
achiev motor mileston spinraza patient achiev vs
sham group figur drug demonstr efficaci type
patient therefor expect spinraza still use exist patient
patient current spinraza like continu drug rather switch
assess spinraza good transform drug
patient sma rather new therapeut option gene therapi might
better newli diagnos babi patient
may re-pres american academi neurolog meet
report patient nurtur trial aliv none
requir tracheostomi perman ventil also abl sit without
support abl walk assist could walk without
assist new safeti concern
mileston chop-intend
mortal patient
compani data hine section point increas abil kick point
increas motor mileston head control roll sit crawl stand walk
improv categori motor mileston worsen
zolgensma spinraza could complementari although target
gene zolgensma could efficaci cost like prevent use
product note zolgensma gene therapi aim help patient produc
function smn protein typic code gene mutat unabl
produc function protein patient sma protein essenti surviv
motor neuron henc surviv motor neuron gene/protein healthi
individu sma patient also back-up gene produc limit
amount function smn protein much gene
level produc goal spinraza upregul product function
smn protein act help modifi splice pre-messeng rna
turn promot express full-length smn protein akin produc
gene target gene zolgensma could produc better result
lower dose sinc gene abl produc function smn
protein spinraza zolgensma could complimentari act
differ defect gene respect believ
payer would cover treatment due cost
earlier develop forecast launch roche/ptc
risdiplam could competit threat long term risdiplam could take
signific market share spinraza pivot clinic data show similar efficaci
spinraza also note roche/ptc current explor use risdiplam
follow spinraza phase jewelfish trial link could provid clinic case
switch spinraza risdiplam highlight oral rout administr
prefer intrathec speak physician inconsequenti
agre argument compani intrathec prefer infant
vs oral fear babi may ingest entir medicin dose intrathec
inject newborn babi invas carri risk difficult clinician
compar firefish endear trial appear favor risdiplam despit
challeng cross-trial comparison compar risdiplam firefish data vs
spinraza endear see better result patient treat risdiplam
chop-intend respond patient sit without support better
surviv note endear trial data patient vs firefish
figur sma type trial comparison risdiplam spinraza
diagnosi month
first dose month
day
sit w/o support
event-fre trial
event-fre month old
end-of-studi visit day
trial cutoff date mortal
patient perman ventil
compar data type patient across risdiplam spinraza trial
difficult differ scale use measur efficaci world muscl
societi meet saw data type patient treat risdiplam
interest efficaci sunfish trial figur includ data sunfish
updat data cherish trial spinraza view
earli determin risdiplam winner vs spinraza see efficaci
agent note spinraza disadvantag administ
charl martineau univers toronto figur sma type trial comparison risdiplam spinraza
age
age
total
death drug-rel
safeti find lead
withdraw patient
sae unrel
headach back pain due
inject csf
screen yr
symptom onset month
abil sit without support
abil walk support
abil walk independ
total mfm chang baselin
mean sd
total mfm chang baselin
median rang
proport pt
improv baselin
gain abil stand alon
see risk biogen sma franchis competit incid
preval market competit threat zolgensma risdiplam could
pressur incid preval compon sma market
henc below-consensu estim think spinraza place
treatment paradigm like strong competit gene therapi
oral therapeut current valuat like underappreci competit threat
potenti multipl contract data competit program
 may increasingli import
analysi may need help reacceler revenu earn
growth share may screen cheap rel large-cap biotech
major pharma stock pe vs think low multipl justifi
owe current growth profil view may one way improv
multipl growth profil believ acquisit nightstar
like result signific improv
screen biotech compani market cap higher believ
busi size could use partner screen compani
could fit strateg neurolog rare diseas focu like
enough project revenu help chang growth trajectori see figur
rank compani rate scale low strateg fit unrel
therapeut area high strateg fit relat therapeut area potenti
near-term ep accret small mid-cap space sarepta neurocrin
screen well basi base premium achiev complet acquisit
biotech space ytd believ premium current share
price/enterpris valu would ration among larger cap alexion biomarin
also screen well though due size deal structur would like akin
merger cash debt stock might involv outsid market cap
group also examin given competit threat pose
biogen sma franchis compani cover credit suiss analyst
analysi use estim neurocrin sarepta biomarin alexion
cover use factset consensu given acquisit
histori expect execut major acquisit near term
howev think given manag statement capit avail
employ toward and/or buyback might consider light
aducanumab discontinu
compani cover cs analyst martin auster alexion op pt biomarin op pt sarepta therapeut op pt
earlier year biogen cfo discuss potenti capit transact share
repurchas use methodolog updat recent deal buyback
estim capac may either
issu share debt beyond compani discuss execut deal
furthermor compani recent indic interest
acquir earlier-stag asset failur aducanumab may mean may
consid later-stag asset figur estim deal capac
charl martineau univers toronto includ recent transact nightstar author
among small/mid-cap neurocrin sarepta therapeut
three compani approxim market cap assum
premium base analysi recent transact januari
ytd see figur compani oper neurosci field
commercial-stag product promis pipelin could provid longer-
term option neurocrin sarepta also gene therapi
figur biotech transact valu premium
charl martineau univers toronto figur biotech transact valu premium
therapeuticsrec approv zulresso postpartum depress
consensu expect zulresso current expect
increas highlight potenti attract revenu opportun think
potenti combin could improv growth trajectori
revenu base also contribut earn growth howev assum
potenti purchas premium would requir debt financ transact ep impact
appear limit see figur assum purchas premium
conserv could acquir approxim assum
cash new debt equiti issu
assum equiti issuanc capac financ
transact cash hand debt issuanc assum would dilut
share purchas compani
highlight zulresso psychiatri space see adjunct biogen
core focu neurolog howev earli day zulresso launch
could hamper initi sale would meaning impact top line
near term addit drug administr difficult given mother
recent child must infus hospit set hour compani
later-stag pipelin asset develop includ major depress disord
insomnia parkinson diseas think acquisit small-molecul drug vs
broader platform would effici effect way fill
pipelin howev revenu upsid could help near term furthermor
headquart cambridg could eas integr two
charl martineau univers toronto figur illustr scenario analysi potenti combin
interest rate new debt
new interest deal-rel debt issuanc
weight average share calcul ep
new share issu transact
purchas price premium
market cap premium
note analysi perform non-gaap basi exclud amort deal relat intang
neurocrin biosciencescommercial-stag compani asset
broad neurology-focus pipelin full assess neurocrin see
initi coverag high-level think revenu upsid ingrezza
tardiv dyskinesia royalti orilissa endometriosi like uterin fibroid
could meaning contributor sale estim neurocrin revenu
pro-forma basi estim could
increas five-year compound-annual-growth-rate top line includ
impact interest expens complet deal estim ep could increas
impli increas versu alon see figur
assum purchas premium conserv could acquir
neurocrin approxim assum cash new debt
equiti issu
asid ingrezza orilissa neurocrin rich pipelin core
outperform rate includ congenit adren hyperplasia gene therapi
partnership voyag develop treatment parkinson diseas pd
friedreich ataxia believ complementari current neurolog
focu especi rare diseas neurodegen diseas believ
gene therapi program pd could complementari current work
view combin neurocrin could fit compani
would acquir two current revenu stream strong neurology-focus pipelin
howev ingrezza orilissa remain earli stage launch may
meaning chang near-term revenu trajectori neurocrin locat
san diego make integr challeng
charl martineau univers toronto figur illustr scenario analysi potenti neurocrine-biogen combin
interest rate new debt
new interest deal-rel debt issuanc
weight average share calcul ep
new share issu transact
purchas price premium
market cap premium
note analysi perform non-gaap basi exclud amort deal relat intang
sareptacommercial-stag compani therapeut treat duchenn
therapi platform could gener sale accord small mid-cap
team assum drug ultim approv estim could
chang revenu outlook small mid cap team estim
potenti revenu overal product sale increas improv
top line compound-annual-growth-rate includ impact
interest expens complet deal estim ep could increas
see figur estim could acquir sarepta
use combin cash hand new debt equiti issuanc
sarepta offer extens platform duchenn muscular dystrophi therapi exon-
skip gene therapi compani also develop program charcot-
marie-tooth diseas mucopolysaccharidosi iiia limb-girdl muscular dystrophi
asset would fit neurolog rare diseas focu locat
headquart cambridg would allow eas integr
figur illustr scenario analysi potenti sarepta-biogen combin
interest rate new debt
new interest deal-rel debt issuanc
weight average share calcul ep
new share issu transact
purchas price premium
market cap premium
note analysi perform non-gaap basi exclud amort deal relat intang
larger scale biomarin alexion
explor two larger compani also screen well strateg sens view
larger size compani deal
compani would like requir issuanc stock addit cash/debt
biomarinmultiproduct orphan compani gene
hemophilia smaller compani alexion also see
possibl could acquir biomarin structur mix cash
addit debt stock biomarin solid revenu base rare diseas mainli
focus enzym replac therapi ert would rel synergist
biogen sma franchis greatest upsid potenti would biomarin gene
therapi program valrox hemophilia small mid-cap biotech team estim
peak sale could drug biomarin current revenu base
auster model expect grow assum contribut
vosoritid hemophilia gene therapi could alter revenu
trajectori given current consensu revenu expect would see
combin biomarin potenti increas revenu
oper incom five-year compound-annual-growth-rate could possibl increas
factor potenti share dilut cost synergi interest expens estim
pro forma ep would
see figur note oper incom may increas
would signific dilut share issuanc requir estim biogen
could acquir biomarin structur mix cash
debt share slightli small/midcap biotech
team acquisit price approxim
biomarin offer access late-stag gene therapi see deal
like compani divest hemophilia made strateg
move away hemophilia see get back space follow
spin-off bioverativ biomarin locat san francisco bay area
would harder integr may limit cost synergi given sg
expens requir market sell ert around world rare diseas
charl martineau univers toronto figur illustr scenario analysi potenti biomarin-biogen combin
purchas price premium
market cap premium
interest rate new debt
new interest deal-rel debt issuanc
weight average share calcul ep
new share issu transact
note analysi perform non-gaap basi exclud amort deal relat intang
alexionorphan diseas compani solid revenu base among
compani screen alexion largest market cap
larg size potenti combin alexion would akin
merger assum would requir use cash debt
stock issuanc combin alexion would larger
alexion solid revenu base soliri ultomiri strensiq kanuma
small/mid-cap biotech team estim revenu increas
could chang growth trajectori revenu base
alexion beyond current compani stand-alon
alexion complet focus neurolog gmg indic
soliri also develop asset neuromyel optica spectrum disord
nmosd wilson diseas wilson therapeut acquisit april
also neurolog
upsid potenti transact size lie potenti strengthen
revenu base compani realiz cost synergi could help improv
long-term earn margin see figur
alexion locat boston area would make eas
integr believ may challeng alexion still
locat new alexion current cfo paul clanci
indic know busi could navig alexion
legaci busi risk execut believ
potenti bring valu sharehold especi post-aducanumab
charl martineau univers toronto figur illustr scenario analysi potenti alexion-biogen combin
interest rate new debt
new interest deal-rel debt issuanc
weight average share calcul ep
new share issu transact
purchas price premium
market cap premium
note analysi perform non-gaap basi exclud amort deal relat intang
therapeut candid screen market cap
small meet initi criteria howev look criteria
defens posit potenti earn accret screen well pro
forma analysi use consensu estim see accret assum
combin financ use cash hand howev potenti gain
revenu oper incom may enough improv growth profil
avoid need futur asset see figur
figur illustr scenario analysi potenti therapeutics-biogen combin
interest rate new debt
new interest deal-rel debt issuanc
weight average share calcul ep
new share issu transact
purchas price premium
market cap premium
note analysi perform non-gaap basi exclud amort deal relat intang
major pharma large-cap biotech gilead vertex regeneron
would unlik acquir given weaker pipelin declin
commerci busi believ major pharma large-cap biotech would
interest combin ms busi remain stabl cash
gener sma still provid revenu opportun believ less appetit
deal scale bristol celgen even revlimid celgen broader
late-stag pipelin like accret bristol colleagu vamil divan
work deal first-look follow-up deeper look wellington opposit holt
analysi howev possibl becom attract takeout
candid could increas share remain depress declin
nightstar could expand gene
follow late-stag failur aducanumab see larg gap within biogen
pipelin compani later-stag asset noth nearli
pioneer stock move aducanumab later-stag asset
focus vixotrigin trigemin neuralgia move phase
glibenclamid lhi stroke current phase recent acquir asset
nightstar transact nsr-rpgr view none
program significantli move needl term revenu growth
earn growth multipl expans think earlier work amyotroph later
sclerosi al progress supranuclear palsi psp parkinson diseas
interest earli us assign meaning valu focu analysi
look pipelin note asset either clinic trial
neg data limit clinic data believ gener low probabl
success see figur lack excit pipelin core under-perform
thesi share see pipelin drive meaning upsid
figur pipelin phase
associ schizophrenia
clinic trial
strokebett set vs pain still challeng
develop path mix phase data
biogen phase asset glibenclamid high affin
channel inhibitor studi reduc brain swell edema ischem
stroke patient larg hemispher infarct transient receptor potenti
melastatin channel link sulfonylurea receptor channel form
channel demonstr increas product neural cell
anim stroke mehta et al believ target help mediat edema
cell death breakdown blood-brain barrier state
death first week follow ischem stroke attribut edema drug
grant orphan drug design fast-track statu unit state
approv could gener risk-adjust sale
phase data potenti expect began phase charm
clinicaltri gov entri septemb still enrol patient current estim
peg data trial target patient larg hemispher infarct
trial treatment must administ iv bolu hour within hour
symptom onset primari endpoint mr prior
phase games-rp trial except exclud patient receiv
decompress craniotomi dc trial howev exclud patient
dc prior enrol modifi rankin scale mr wide use clinic
outcom measur stroke clinic trial measur degre disabl
depend scale healthi death daili activ stroke
patient trial expect complet state potenti launch could
expect earli
mix phase data lead rel lower po assign
lower po usual post-phas phase asset base mix
phase data previous fail attempt develop stroke asset tysabri
phase data fail meet primari endpoint although posit trend
measur hemispher swell midlin shift far unsuccess
deliv stroke asset give us less confid compani abil
execut therapeut area
phase games-rp miss primari endpoint primari endpoint mr
decompress craniotomi reach statist signific figur
remedi pharmaceut develop asset point discrep
site use decompress craniotomi dc reason reach
statist signific trial popul small could meaning affect
signific nevertheless larg phase trial provid clariti drug
efficaci data regard secondari endpoint larg posit
reduct mortal glibenclamid vs placebo first day total
death occur first day greater proport placebo group
vs death treatment group addit posit endpoint compar placebo
includ improv hemispher swell improv
midlin shift statist signific data trend toward posit
clinic effect lesion swell mortal measur day
furthermor safeti issu report
death day
improv mr
compani data credit suiss estim modifi rankin scale mr common outcom measur determin degre
disabl depend daili activ peopl suffer stroke scale run perfect health
uncrowd field stroke could present interest opportun
still enough move needl long-term tissu plasminogen activ
tpa mainstay class treat acut ischem stroke highli effect clot --
bust drug recommend within hour stroke symptom roch activas
alteplas current standard care patient also commonli start statin
therapi acut ischem stroke toler oral medic statin
shown decreas recurr event outsid alteplas acut
pharmacolog treatment approv expect posit
complementari agent alteplas could infus acut ischem stroke
therefor see alteplas competit threat potenti
extend treatment time hour sinc alteplas recommend
hour given hour symptom appear view
import differenti sinc provid potenti option patient miss
hour window tpa
deal structur purchas cirara glibenclamid remedi
pharmaceut may known acquisit
report gaap-onli charg in-process respons
futur develop commerci remedi share cost
develop remedi also entitl receiv payment upon regulatori
approv royalti futur commerci sale
success develop prior stroke asset februari announc
stop studi tysabri natalizumab acut ischem stroke fail primari
endpoint second round phase trial latest trial failur
repeat phase action studi commenc year like recent
studi also fail primari endpoint phase studi primari endpoint
chang infarct volum use imag composit score base mr
barthel index posit data action endpoint similar
phase games-rp trial also fail mr two drug
differ mechan therefor could still see efficaci addit
issu regard decompress craniotomi confound
approv estim unadjust ww sale model
assum launch market penetr first year grow
figur market model outsid assum smaller
market reach unadjust sale see figur given lack
viabl option approv estim high market penetr due low
competit complementari use alteplas addit patient could
cover hour beyond alteplas indic gross price
base price alteplas assum administ
singl time complianc rate estim expect patient treat
inpati therefor receiv infus would increas complianc significantli
current assum protect us patent least
method treat neural swell method
treat spinal cord injuri compound inhibit ncca-atp channel assum
year patent term extens lead impli exclus outsid us
ip vumer extent composit matter
figur stroke market build adjust unadjust sale
patient diagnos hour
probabl success
figur stroke ou market build adjust unadjust sale
patient diagnos hour
discount us list price
probabl success
pain programlow confid vixotrigin pain trigemin
even success think unlik opportun small
indic vixotrigin would need success larger small fiber
neuropathi trial make meaning differ
vixotrigin acquir includ asset converg
pharmaceut up-front payment addit mileston revenu
drug inhibit sodium channel encod gene
channel control passag sodium sensori neuron believ
associ pain patient experienc trigemin neuralgia tn tn
neurolog condit result recurr brief episod electr shock-lik pain
head face trigemin nerv suppli sensori motor neuron mostli
face case tn caus nerv root compress abnorm arteri
vein caus includ compress vestibular schwannoma meningioma
cyst pathogenesi diseas fulli understood
phase trigemin neuralgia initi expect delay trial
initi receiv fda feedback plan begin phase trial link
trial tn toward end estim patient expect trial
vs enrol patient phase trial link trial studi period increas
week phase
despit progress phase develop tn exclud potenti revenu
contribut model low po reflect lower confid vixotrigin due
mix data small phase trial
fail attempt use vixotrigin treat pain lumbosacr radiculopathi
plsr
unsuccess use inhibitor competitor treat form
phase trial tn plsr meet primari endpoint make difficult
much confid area addit vixotrigin treat pain
lumbosacr radiculopathi plsr discontinu octob fail
meet primari secondari endpoint view failur treat differ form
neuropath pain bode well drug use tn addit
inhibitor class suspend competitor neuropath pain indic roch
teva partner xenon pharmaceut discontinu drug
treat neuropath pain respect
phase primari endpoint gener well-toler
primari endpoint differ number treatment failur placebo
vixotrigin trial link manuscript patient vs patient
classifi treatment failur respect see figur advers event
gener low group treatment group experienc headach pyrexia
fever nasopharyng sleep disord tremor se occur patient
compar patient patient headach dizzi diarrhea
vomit placebo group find trial result particularli meaning
consid lack statist signific small sampl patient complet
trial drug appear rel safe
figur phase vixotrigin tn
approv uncertain current data small patient popul
competit despit rel small market tn new therapi
control pain tn per patient estim experi tn
amount around patient unit state carbamazepin first-lin
treatment gener effect except patient experi signific side
effect seriou sometim fatal skin reaction includ toxic epiderm necrolysi
stevens-johnson syndrom addit aplast anemia anoth seriou
side effect carbamazepin requir frequent blood monitor therefor feel
room addit player space
gene therapi compel
therapeut difficulti commerci
later-stag gene therapi think commerci might
challeng week phase trial aducanumab discontinu biogen
announc would acquir nightstar therapeut cash move
provid compani posit gene therapi space specif rare
ophthalm condit gener trend pivot gene therapi highlight
recent move roch acquir spark therapeut novarti acquir avexi
see move long-term hedg gene therapi market acquir platform
could expand multipl indic note current later-stag
indic unlik move revenu needl next year late-stag
asset acquir deal could commerci viabl although expect
blockbust drug asset
acquir later-stag asset nightstar nsr-
rpgr smaller indic patient choroideremia nsr-
patient x-link retin pigmentosa nsr-rpgr
expect addit data nsr-rpgr program first phase
preliminari data trial suffici regulatori approv must
conduct addit phase trial satisfi regul expect top-lin data
program second half think phase data could
enough file regulatori approv estim combin could gener
approxim peak sale nsr-rpgr like gener think
price paid fair note market hardli enough chang growth
profil post-aducanumab preclin asset acquisit could address
larger market given lack clinic data exclud valu
assess transact figur overview nightstar pipelin
charl martineau univers toronto figur pipelin acquir nightstar
advantag acquir gene therapi platform current
commerci prospect remain small given histori space
surpris compani step back ophthalmolog gene therapi market
decemb split appli genet corpor agtc
agtc competitor nightstar focus similar asset
concern nightstar center scienc think gene therapi
eye somewhat valid rather small market xlrp
choroideremia note spark luxturna use retin dystrophi first
approv gene therapi sale anem best also
understand peopl age incid ophthalmolog condit increas
argument support deal note less like
genet relat incid wet age-rel macular degener
wamd market address regeneron roch like novarti
technic point view like eye-focus gene therapi platform
easier access direct inject non-invas monitor lower viral load treat
dissemin lower potenti wide-rang side effect despit advantag
think commerci opportun small
clinic proof-of-concept choroideremia patient treat show
improv read least letter visual acuiti chart one year vs
untreat popul see figur data show
higher rate vision retent compar night natur histori studi one year
patient receiv lost letter use visual acuiti chart
compar patient untreat group see figur trend widen
month group vs untreat group
tissu cite manufactur advantag
charl martineau univers toronto figur phase dataimprov visual acuiti
phase year
night natur histori year
figur proof-of-concept choroideremia
phase data nsr-rpgr program demonstr interest efficaci
accept safeti profil note patient cohort
patient cohort demonstr earli efficaci signal see figur
compani suspect inflamm may affect efficaci cohort
regardless data earli need see clearer efficaci signal
patient fulli comfort program compani current enrol
phase dose expans studi addit phase studi like requir
figur choroideremia market model row figur
xlrp market model row
charl martineau univers toronto figur phase data nsr-rpgr studi xlrp
figur choroideremia market build adjust unadjust sale
us popul million
total patient us
preval chm us
list price eye
probabl success
figur choroideremia ou market build adjust unadjust sale
ou address popul million
preval chm ou
list price eye
probabl success
figur nsr-rpgr x-link retin pigmentosa market build adjust unadjust sale
us popul million
total xlrp patient us
preval xlrp us
list price eye
probabl success
figur nsr-rpgr x-link retin pigmentosa ou market build adjust unadjust sale
ou address popul million
preval xlrp ou
list price eye
probabl success
beyond stroke pain nightstar acquisit littl els
pipelin believ could help chang near-term commerci
trajectori success program parkinson diseas al
psp could meaning opportun simpli
enough clinic data evid support inclus valuat
compani present phase data patient
rare form al impact al popul
impress work difficult area remain extrem high unmet
need believ like defunct aducanumab program high
risk would like see pipelin later-stag program support
robust clinic data compar peer gener less bullish
prospect pipelin asset point would
drive revenu earn also note failur
aducanumab unlik success confirmatori phase trial
hope success ad like lay within anti-tau develop program
face challeng ocrevu crowd
biogen ms franchis like face near-term headwind ocrevu
recent/upcom approv oral space proprietari survey highlight
potenti headwind across ms franchis led ocrevu take share
tysabri crowd oral market overal less enthusiasm older inject
 plegridi avonex think potenti eros fulli appreci
consensu forecast figur ms franchis estim book sale
ocrevu royalti vs consensu expect time expect continu
crowd market bolster novel asset oral novartiss mayzent
celgen ozanimod iv roch ocrevu space also concern
approv vumer alter trajectori oral market point
crowd less prescrib familiar survey bright spot could
number ms patient continu increas benefit blunt
competit increas figur estim address ms patient
follow key take-away survey support thesi ms busi
physician satisfact ocrevu high increasingli attract option
potenti expens tysabri older-iv therapi
ocrevu usag treatment-nav set remain low patient start
ocrevu good oral whole solv crowd issu
tecfidera seem stabl near term competit oral segment
could hamper usag vumer low awar could blunt launch
figur ocrevu royalti paid
segment conduct survey prescrib neurologist experi treat
multipl sclerosi investig trend diseas manag on-going impact
ocrevu sentiment toward variou therapi develop respond report
see ms patient per month averag mean total
ms patient relapsing-remit multipl sclerosi rrm patient primari
progress multipl sclerosi ppm patient patient cover survey
physician indic privat insur cover medicaid
cover medicar
prescrib prefer oral therapi treatment-nav popul like
persist degre ocrevu cannib set proprietari
ms survey result indic ocrevu increasingli popular oral therapi
still prefer major treatment-nav case believ unlik
chang near futur respond report averag new treatment-
nave rrm patient treat ocrevu receiv oral therapi see
figur although respond indic would increas ocrevu usag
next year indic usag oral therapi also like
increas see figur data suggest ocrevu primarili take share
charl martineau univers toronto inject therapi copaxon avonex plegridi moder impact
iv option includ tysabri lemtrada littl impact oral therapi
figur report percentag new treatment-
nave rrm patient treat therapeut class
figur anticip one-year chang
prescript habit treatment-nav rrm
figur percentag report ocrevu usag prior
treatment-nav usag ocrevu increasingli like use
treatment-experienc patient like expens biogen tysabri despit
indic increas willing use report histor ocrevu usag
treatment-nav case see figur respond plan increas
usag first therapeut switch mani expect decreas usag
inject therapi follow year see figur think trend would
impact biogen tysabri model comprehens ms model iv
therapi receiv royalti ocrevu believ
enough off-set tysabri revenu eros use inject therapi
interferon copaxon etc also like declin time account
interferon forecast five-year compound-annual-growth-rate
figur anticip one-year chang prescript habit patient first switch
high satisfact report ocrevu experi drive increment
usag also neg tysabri experi ocrevu gener
posit respond indic high level satisfact drug efficaci
report high level patient satisfact see figur
figur prescrib satisfact ocrevu experi across variou metric
neither satisfi dissatisfi
treatment select treatment decis primarili driven safeti efficaci
diseas sever see figur among secondari factor patient experi
consider conveni request priorit next follow
charl martineau univers toronto cost-to-pati reimburs support major respond report iv
therapi includ ocrevu restrict term payer polici see figur
figur averag report prioriti factor
figur percentag respond rank
therapeut class sever payer
patient
oral ms franchis could face headwind competit emerg vumer
unlik panacea franchis among oral tecfidera led
class report usag expect see figur howev better oral
becom avail could see eros class expect conveni
minim invas rel favor payer support oral therapi mitig
eros ocrevu particularli treatment-nav anticip prefer
oral persist launch vumer potenti enhanc toler could
creat opportun vumer serv commerci successor tecfidera
potenti provid franchis measur protect eros
note key dose patent expir februari thought
provid long-term protect tecfidera recent ipr challeng
patent could howev put revenu risk rule expect earli
think dose patent weaker protect vs composit matter regardless
tecfidera ip increasingli competit market cast doubt vumer abil
note us vumer protect least ou
us assum similar protect outsid
us still gener entrant could use mandat usag gener oral ahead
brand oral tecfidera vumer us ou address
charl martineau univers toronto figur percentag respond rank oral therapi frequenc
use rrm patient
lack prescrib awar crowd pipelin lead us take
conserv view vumer potenti respond report lowest level
familiar vumer rel product develop see figur
expect head-to-head gi toler data vumer vs tecfidera expect mid-year
long-term safeti data expect drive increment awar
excit anticip focus elsewher
figur level familiar variou ms product develop
familiar product
data
familiar
compani
familiar clinic data
high excit competitor tepid sentiment toward vumer suggest
launch veloc may restrain respond indic moder
high high level excit next-gener oral therapi
develop celgen ozanimod
requir novartiss mayzent siponimod see figur contrast excit
vumer lowest among group respond indic vumer
warrant usag consider highest proport among product
assum
charl martineau univers toronto figur degre excit toward variou ms product develop
moder high high excit
assum approv first-dos monitor requir
headwind underli ms franchis could appreci
consensu overal believ ms continu face headwind across
segment tysabri risk busi model detail revenu
product figur expect ocrevu continu take share
among treatment-experienc patient iv inject therapi tysabri
avonex plegridi long term believ vumer sourc
signific growth think competit crowd affect vumer commerci
ms sale product
royalti paid biogen
ms sale product
royalti paid biogen
biosimilar busi gener end-us
sale still enough differenti
biosimilar busi leverag biolog develop commerci
knowhow must share profit jv partner similar also
focus develop effort biosimilar howev unlik
fewer asset must share profit samsung biolog via joint ventur entiti
samsung bioepi own furthermor scope
biosimilar busi limit anti-tnf vs much broader oncolog
immunolog rare diseas focu
per agreement samsung bioepi merck merck follow
right biosimilar commerci etanercept ww exclud /eu/japan
eu/russia/turkey trastuzumab ww exclus read indic
could commerci biosimilar enbrel etanercept ip
drug expect expir late given samsung agreement
merck see much expans beyond anti-tnf europ
limit eu commerci infliximab adalimumab /eu
commerci etanercept given limit estim peak end-us
sale could vs end-us sale biosimilar
portfolio figur biosimilar build figur biosimilar
contribut base busi figur forecast base
benepali biosimilar enbrel etanercept
flixabi biosimilar remicad infliximab
imraldi biosimilar humira adalimumab
profit share samsung bioepsi
share jv cog
share jv
share jv
payment jv profit split
charl martineau univers toronto figur biogen contribut biosimilar
includ market product exclud pipelin
per commerci agreement ink agre commerci
three anti-tnf europ also benepali japan book sale
asset product revenu compani also recogn expens
associ sale market sg line item applic royalti payment
mainli sale imraldi includ cog line main
share profit loss relat commerci agreement recogn
collabor profit/loss share line item assum sale
market expens associ biosimilar busi approxim
lower compani sg expens percent sale product
cost good fulli book sale revenu earn impact
significantli blunt account profit-shar samsung biolog
see benefit headwind biosimilar busi benefit
capac develop commerci large-molecul drug notabl
tysabri
rel easi lower-risk cash flow need spend level
develop innov molecul
start alreadi demonstr success actual cash flow
still see downsid biosimilar busi
space get crowd multipl player drive net price
requir competit contract novartis/sandoz
must share profit jv partner samsung biolog
case novartis/ sandoz
 launch plan current portfolio product compani
fulli rule note commerci
current portfolio limit anti-tnf miss opportun
oncolog rare diseas
think biosimilar franchis fairli valu estim
dcf analysi share see substanti upsid franchis
biosimilar busi warrant higher multipl figur
view biosimilar busi end user sale vs consensu expect
forecast incom statement balanc sheet statement cash flow
project fy revenu forecast non-
ep figur incom
statement balanc sheet found figur statement cash flow
found figur
total revenu
total revenu
total revenu
amort intang asset
total revenu
sale right
profit tax
equiti loss investe net tax
non-controlling interest net tax
weight average share use calcul dilut ep
gross margin product sale
oper margin total revenu
net margin total revenu
cash equival
prepaid expens current asset
properti equip net
accru expens
commit conting
accumul comprehens loss
charl martineau univers toronto figur biogen statement flow
statement flow
chang asset liabil
accru expens liabil
net cash use oper activ
purchas market secur
sale market secur
net cash use invest activ
purchas treasuri stock
payment issuanc common stock
excess tax benefit stock-bas compens
purchas borrow
repay debt oblig
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
holt view
run project holt valuat framework result
warrant valu per share target price
holt credit suiss proprietari methodolog compani analysi stock
select deliv object global consist view compani
holt use perform metric known return invest cfroi
adjust account distort compar econom perform across
sector region time appl appl basi holt valuat methodolog
base discount cash flow framework number distinguish featur
includ uniqu way calcul termin valu firm cost capit
base forecast holt dcf get warrant valuat per
share target price mainli due holt rel lower discount rate
util nomin wacc holt discount rate state real
term bibb note holt discount rate differ tradit
method deriv wacc holt discount rate forward-look market-
deriv expect return asset holt model self-consist system
discount rate tune market price long-term cash flow project holt use
market impli discount rate countri yield requir investor base current
aggreg stock valuat appli adjust compani specif leverag
size act risk factor refer holt us market discount rate
long-term averag global discount rate beyond earn holland
beyond holt dcf framework appli mean revers methodolog
calcul termin valu assum cfroi discount rate fade gradual
long term averag asset growth fade reach averag growth
also run sensit analysi show valuat
sensit top line growth indic get target price holt impli
neg growth
charl martineau univers toronto figur holt analysi
cs peer relationship biogen
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag figur
figur cs peer relationship map
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss larg cap
alzheim aducanumab primer
includ valu alzheim asset valuat note
public partnership eisai develop
on-going review thought asset provid brief primer
alzheim section
less enthusiasm follow aaic present initi data
report aaic indic slower declin adas-cog mg
twice-monthli group vs placebo addit data show less declin
adcom group vs placebo recal drug meet
criteria success adcom primari endpoint base bayesian
analysi decemb independ data monitor committe later
month aaic full data present trial start realli show
concern start disclosur european regul requir carrier
